

**Freedom of Information Act 2000**

**The Royal Cornwall Hospitals NHS Trust Response to Information request**

**Date Request Received: 16<sup>th</sup> June 2025**

**FOI Ref No 29205**

**Requested Information:**

Q1. How many patients were treated in May 2025 (or latest available month) by the gastroenterology department with the following biologic drugs?

- Etrasimod
- Filgotinib
- Golimumab
- Mirikizumab
- Ozanimod
- Risankizumab
- Tofacitinib
- Upadacitinib
- Ustekinumab (Stelara)
- Ustekinumab Biosimilar
- Vedolizumab

**Response:**

• Etrasimod	<b>0</b>
• Filgotinib	<b>1</b>
• Golimumab	<b>1</b>
• Mirikizumab	<b>0</b>
• Ozanimod	<b>1</b>
• Risankizumab	<b>12</b>
• Tofacitinib	<b>6</b>
• Upadacitinib	<b>36</b>
• Ustekinumab (Stelara)	<b>7</b>
• Ustekinumab Biosimilar	<b>117</b>
• Vedolizumab	<b>145</b>



**Royal Cornwall Hospitals**  
NHS Trust

**Attachment(s):**

No Attachment(s)

**Date Response sent: 19<sup>th</sup> June 2025**